SRTA · XBRL financial data

Strata Critical Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SRTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Sep 30, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	50,526	146,120	225,180	248,693	197,141
Cost of revenue	—	39,721	123,845	183,058	189,774	156,015
Gross profit	—	—	—	—	29,589	41,126
Selling, general and administrative	—	—	—	—	50,856	60,875
General and administrative	—	29,922	62,510	95,174	81,711	—
Total operating expenses	678	(24,943)	(36,570)	(33,226)	52,114	63,479
Operating income (loss)	(678)	(24,093)	(53,529)	(68,117)	(33,926)	(22,353)
Other income (expense)	—	(19,602)	25,497	10,575	—	—
Income tax expense (benefit)	210	(3,643)	(772)	(1,466)	(255)	0
Net income (loss)	(20,522)	(40,052)	(27,260)	(56,076)	(27,307)	41,347
Earnings per share, basic USD per share	—	(0.93)	(0.38)	(0.76)	(0.35)	0.50
Earnings per share, diluted USD per share	—	(0.93)	(0.38)	(0.76)	(0.35)	0.50
Weighted average shares, basic thousands of shares	—	42,884	71,238	73,524	77,499	82,092
Weighted average shares, diluted thousands of shares	—	42,884	71,238	73,524	77,499	82,092

Fiscal years (SRTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Sep 30, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	846	6,952	43,296	27,873	18,378	30,968
Marketable securities	—	297,175	150,740	138,264	108,757	30,263
Marketable securities, non-current	276,943	—	—	—	—	—
Accounts receivable	—	3,765	10,877	21,005	21,591	39,958
Prepaid and other current assets	—	5,925	12,086	17,971	10,747	24,739
Total current assets	896	314,447	218,126	206,261	160,742	126,192
Property and equipment, net	—	1,958	2,037	2,899	30,918	36,444
Right-of-use asset	—	654	17,692	23,484	8,876	3,107
Goodwill	—	13,271	39,445	40,373	41,050	88,210
Total assets	277,839	343,394	325,025	294,938	256,675	325,472
Total current liabilities	391	9,531	26,607	35,491	22,726	19,794
Total deposits	410	—	—	—	—	—
Lease liability, non-current	—	222	14,970	19,738	6,018	2,655
Total liabilities	46,782	52,165	50,536	60,638	34,737	46,400
Accumulated deficit	(18,191)	(77,190)	(103,678)	(159,754)	(186,898)	(145,551)
Total stockholders' equity	5,000	291,229	274,489	234,300	221,938	279,072
Total liabilities and equity	277,839	343,394	325,025	294,938	256,675	325,472
Common shares outstanding (cover page) thousands of shares	—	70,553	72,036	75,433	79,694	86,989

Fiscal years (SRTA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Sep 30, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(20,522)	(40,052)	(27,260)	(56,076)	(27,307)	41,347
Stock-based compensation	—	9,621	8,277	12,501	19,893	17,832
Depreciation and amortization	—	596	5,725	7,111	5,962	8,185
Net cash from operating activities	(794)	(15,615)	(37,130)	(32,349)	(2,519)	(48,914)
Purchases of property and equipment	—	297	730	2,109	30,875	9,595
Net cash from investing activities	335	(321,338)	79,340	17,089	(1,016)	69,750
Share repurchases	—	—	—	0	244	0
Net cash from financing activities	—	332,259	(1,084)	(76)	(5,759)	(8,912)
Net change in cash	(460)	(4,694)	41,198	(15,402)	(9,374)	11,585

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Strata Critical Medical	35,136	74,081	9,458*	89.3M	—	Q3 FY26 10-QSep 30, 2026
Talkspace	39,159	61,672	11,385*	165.8M	—	Q2 FY26 10-QJun 30, 2026
DocGo	25,233	73,425	(9,242)*	98.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
InnovAge Holding	119,253	264,757	28,742	136.5M	—	Q1 FY27 10-QSep 30, 2026
U S Physical Therapy	24,887	214,059	34,370*	14.9M	—	Q2 FY26 10-QJun 30, 2026
LifeStance Health Group	225,943	435,354	99,912*	382.1M	—	Q2 FY26 10-QJun 30, 2026
Pennant Group	15,273	297,984	21,830*	34.9M	—	Q2 FY26 10-QJun 30, 2026
Omada Health	221,712	87,835	4,007*	61.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.